Prestige Consumer Healthcare Raised 2023 Diluted EPS Guidance To Approximately $4.33 From Prior Guidance Of $4.27-$4.32 Versus Consensus Of $4.32
Portfolio Pulse from Benzinga Newsdesk
Prestige Consumer Healthcare has increased its diluted EPS guidance for 2023 to approximately $4.33, up from the previous range of $4.27-$4.32, surpassing the consensus estimate of $4.32.
February 08, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prestige Consumer Healthcare has revised its 2023 diluted EPS guidance upwards to about $4.33, exceeding analysts' expectations.
Raising EPS guidance typically signals a company's stronger-than-expected financial health and profitability, which can lead to positive investor sentiment and potentially increase stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100